Review of Urological Complications in BCG Immunotherapy for Nonmuscle Invasive Bladder Cancer

Intravesical immunotherapy with BCG for the treatment of nonmuscle invasive bladder cancer is used routinely, urological complications can be variable from self-limited to some that can put the patient's life at risk, in addition, the complications can develop immediately after instillation or years after the end of treatment. India Bacillus Calmette Guerin (BCG) was approved by the Food and Drug Administration (FDA) in 1990, it´s a live attenuated vaccine derived from Mycobacterium Bovis. Is the standard treatment for intravesical immunotherapy for nonmuscle invasive bladder cancer. Its use is very common in urologists